# A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

> **NCT06258174** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT06258174
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2021-12-22
- **Final completion:** 2021-12-22
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258174, "A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06258174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*